FIG. 2.

Sustained efficacy following readministration of AAV-G6Pase. Puppies De, H, and T were treated with AAV2/9-G6Pase at 2 days of age (4×10¹³ vp/kg), and subsequently re-treated with AAV2/7- and AAV2/8-G6Pase as a group to prevent mortality. Blood glucose following 4 and 6 hr of fasting at the indicated ages. Fasting was performed 2 weeks following vector administration, and every 2–3 months subsequently. (A) Dog De. (B) Dog H. (C) Dog T. Dog T had recurrent hypoglycemia and anorexia at 5 months of age that precipitated re-treatment with AAV2/1-G6Pase (Table 1). Color images available online at www.liebertonline.com/hum